Celgene Corporation

États‑Unis d’Amérique


 
Quantité totale PI 1 498
Quantité totale incluant filiales 2 089 (+ 591 pour les filiales)
Rang # Quantité totale PI 878
Note d'activité PI 3,6/5.0    963
Rang # Activité PI 759
Activité incl filiales 3,4/5.0    1 067
Symbole boursier CELG (nasdaq)
ISIN US1510201049
Capitalisation 77,036M  (USD)
Industrie Drug Manufacturers - Major
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

351 267
127 204
340 72
137
 
Dernier brevet 2024 - Methods of treating non-hodgkin ...
Premier brevet 1981 - Production of muconic acid
Dernière marque 2024 - WELBEXUS
Première marque 1996 - Rev

Filiales

19 subsidiaries with IP (571 patents, 20 trademarks)

7 subsidiaries without IP

 S'inscrire grtuitement pour accéder à la liste des filiales

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 P/S Pharmaceutical and biological preparations for human use.
P/S Pharmaceutical and biological preparations for human use.
Invention Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-mor...
Invention Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin...
Invention Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidi...
Invention Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use. Provi...
Invention Tablet compositions. Provided herein is a tablet comprising 2-methyl-1-[(4-[6-(trifluoromethyl)p...
Invention Heteroaryl compounds as ligand directed degraders of irak4. Provided herein are compounds and com...
Invention Transgenic mouse expressing human cereblon. Provided are transgenic mice whose genome comprises ...
Invention Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatmen...
Invention Assessment of bcma in biological samples. Provided herein are methods for detection of soluble B-...
Invention Compounds and compositions for selective degradation of engineered proteins. Provided herein are...
Invention Compounds and compositions for selective degradation of engineered proteins. Provided herein are ...
Invention Compounds and compositions useful as degraders of mk2 kinase. The present disclosure provides com...
Invention Processes for the preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate. Provided are proces...
Invention Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamm...
Invention Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases. ...
Invention Antiproliferative compounds and methods of use thereof. Provided herein is 4-(4-(4-(((2-(2,6-dio...
2023 Invention Substituted imidazo-based compounds as ligand directed degraders of irak3. Provided herein are co...
Invention Heterocyclic compounds as modulators of s1p5. Provided herein are compounds and compositions ther...
Invention Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and met...
Invention Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodie...
Invention Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy. Provided...
Invention Mk2 inhibitors and uses thereof. The present invention provides compounds, compositions thereof,...
Invention Mk2 inhibitors and uses thereof. The present invention provides compounds, compositions thereof, ...
Invention Crystalline forms of 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-1-benzopyran...
Invention Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2...
Invention Methods for treating multiple myeloma. Provided herein are methods of treating multiple myeloma, ...
Invention Substituted imidazopyrazine compounds as ligand directed degraders of irak3. Provided herein are ...
Invention Substituted imidazopyrazine compounds as irak3 binders. Provided herein are compounds and composi...
Invention Substituted pyrazolyl-pyridinyl compounds as ligand directed degraders of irak3. Provided herein ...
Invention Heteroaryl compounds as ligand directed degraders of irak4. Provided herein are compounds and co...
Invention Methods and compositions for reduction of immunogenicity. Provided herein are methods and uses i...
Invention 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatme...
Invention Sirp-α binding proteins and methods of use thereof. Provided herein are compositions, methods and...
2022 Invention Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases. Pr...
Invention Cereblon binding compounds, compositions thereof, and methods of treatment therewith. Provided h...
Invention Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoaze...
Invention Methods of treating multiple myeloma using combination therapy. Provided herein are methods of u...
Invention Pkc-theta modulators. Disclosed are compounds, compositions and methods for treating disease, sy...
Invention Methods of treating b-cell lymphoma using combination therapy. Provided herein are methods of us...
Invention Combination therapies with bcma-directed t cell therapy. Provided herein are methods, compositio...
Invention Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation ...
Invention Methods for treating multiple myeloma. Provided herein are methods of treating multiple myeloma,...
Invention Sulfonamides and their use for treatment of helminthic infections and diseases. Provided herein ...
2021 Invention Heterocyclic compounds and their use for parasitic diseases. Provided herein are compounds of Fo...